Slingshot members are tracking this event:
Gilead Sciences (GILD) plan to fully enroll Phase 3 STELLAR trial for nonalcoholic steatohepatitis (NASH) evaluating selonsertib in treating F3 fibrosis by first half of 2018
Slingshot Insights Explained
Apr 13, 2018
Don’t see a project related to the catalyst you care about?
Related Keywords Nash Fibrosis, Selonsertib, Phase 3, Stellar